|Table of Contents|

The expression and clinical significance of CCT5 in ovarian serous cystadenoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 10
Page:
1893-1897
Research Field:
Publishing date:

Info

Title:
The expression and clinical significance of CCT5 in ovarian serous cystadenoma
Author(s):
WANG Yuxuan12HU Yuexin12LIU Ouxuan12LI Xinru12ZENG Kai12FAN Xiangcheng12LI Xiao12 LIN Bei12
1.Department of Gynecology and Obstetrics,Shengjing Hosipital Affiliated to China Medical University,Liaoning Shenyang 110004,China;2.Key Laboratory of Maternal Fetal Medicine of Liaoning Province,Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province,Liaoning Shenyang 110004,China.
Keywords:
CCT5ovarian serous cystadenomaimmunohistochemistry
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2024.10.023
Abstract:
Objective:To investigate the expression of CCT5 in ovarian serous cystadenoma tissues and its correlation with clinical-pathological parameters and prognosis of ovarian cancer patients.Methods:Immunohistochemical staining was used to evaluate the expression of CCT5 in 50 cases of ovarian serous cystadenoma tissues,22 cases of ovarian borderline tumor tissues,25 cases of ovarian epithelial benign tumor tissues,and 9 cases of normal ovarian tissues.The correlation between CCT5 expression and clinical-pathological parameters and prognosis of ovarian cancer patients was analyzed.Results:CCT5 mainly exhibited cytoplasmic staining.The positive and strongly positive expression rates of CCT5 in ovarian serous cystadenoma tissues (88.0% & 72.0%) were significantly higher than those in the benign group (64.0% & 28.0%) and normal ovarian tissues (66.7% & 22.2%).In ovarian serous cystadenoma tissues,CCT5 expression showed no significant correlation with patients' age,FIGO stage,tumor differentiation,and lymph node metastasis (P>0.05).CCT5 expression significantly influenced the overall survival time of the ovarian serous cystadenoma patients and was identified as an independent risk factor for patient prognosis (P<0.05).Conclusion:CCT5 is highly expressed in ovarian serous cystadenoma tissues and is closely correlated with patient prognosis,making it a potential novel biomarker for tumor screening and diagnosis,as well as a promising target for clinical treatment.

References:

[1] MOUFARRIJ S,DANDAPANI M,ARTHOFER E,et al.Epigenetic therapy for ovarian cancer:promise and progress[J].Clin Epigenetics,2019,11(1):7.
[2] RAHANGDALE L,MUNGO C,O'CONNOR S,et al.Human papillomavirus vaccination and cervical cancer risk[J].BMJ,2022,379:e070115.
[3] MAKKER V,MACKAY H,RAY-COQUARD I,et al.Endometrial cancer[J].Nat Rev Dis Primers,2021,7(1):88.
[4] SAIBIL H.Chaperone machines for protein folding,unfolding and disaggregation[J].Nat Rev Mol Cell Biol,2013,14(10):630-642.
[5] KUBOTA H.Function and regulation of cytosolic molecular chaperone CCT[J].Vitam Horm,2002,65:313-331.
[6] LIU J,HUANG L,ZHU Y,et al.Exploring the expression and prognostic value of the TCP1 ring complex in hepatocellular carcinoma and overexpressing its subunit 5 promotes HCC tumorigenesis[J].Front Oncol,2021,11:739660.
[7] LI Y,LIU C,ZHANG X,et al.CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/beta-catenin signalling pathway[J].Br J Cancer,2022,126(12):1684-1694.
[8] MENG Y,YANG L,WEI X,et al.CCT5 interacts with cyclin D1 promoting lung adenocarcinoma cell migration and invasion[J].Biochem Biophys Res Commun,2021,567:222-229.
[9] OOE A,KATO K,NOGUCHI S.Possible involvement of CCT5,RGS3,and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers[J].Breast Cancer Res Treat,2007,101(3):305-315.
[10] WANG Z,YANG L,HUANG Z,et al.Identification of prognosis biomarkers for high-grade serous ovarian cancer based on stemness[J].Front Genet,2022,13:861954.
[11] CONG Y,BAKER ML,JAKANA J,et al.4.0-A resolution cryo-EM structure of the mammalian chaperonin TRiC/CCT reveals its unique subunit arrangement[J].Proc Natl Acad Sci USA,2010,107(11):4967-4972.
[12] GESTAUT D,ZHAO Y,PARK J,et al.Structural visualization of the tubulin folding pathway directed by human chaperonin TRiC/CCT[J].Cell,2022,185(25):4770-87 e20.
[13] KUBOTA H,HYNES GM,KERR SM,et al.Tissue-specific subunit of the mouse cytosolic chaperonin-containing TCP-1[J].FEBS Lett,1997,402(1):53-56.
[14] DITZEL L,LOWE J,STOCK D,et al.Crystal structure of the thermosome,the archaeal chaperonin and homolog of CCT[J].Cell,1998,93(1):125-138.
[15] PARK J,KIM H,GESTAUT D,et al.A structural vista of phosducin-like PhLP2A-chaperonin TRiC cooperation during the ATP-driven folding cycle[J].Nat Commun,2024,15(1):1007.
[16] SMITH TM,WILLARDSON BM.Mechanistic insights into protein folding by the eukaryotic chaperonin complex CCT[J].Biochem Soc Trans,2022,50(5):1403-1414.
[17] SERGEEVA OA,CHEN B,HAASE-PETTINGELL C,et al.Human CCT4 and CCT5 chaperonin subunits expressed in Escherichia coli form biologically active homo-oligomers[J].J Biol Chem,2013,288(24):17734-17744.
[18] MA X,LU C,CHEN Y,et al.CCT2 is an aggrephagy receptor for clearance of solid protein aggregates[J].Cell,2022,185(8):1325-1345 e22.
[19] JIN M,LIU C,HAN W,et al.TRiC/CCT chaperonin:structure and function[J].Subcell Biochem,2019,93:625-654.
[20] LLORCA O,SMYTH MG,MARCO S,et al.ATP binding induces large conformational changes in the apical and equatorial domains of the eukaryotic chaperonin containing TCP-1 complex[J].J Biol Chem,1998,273(17):10091-10094.
[21]ARAKI K, WATANABE-NAKAYAMA T, SASAKI D, et al. Molecular dynamics mappings of the CCT/TRiC complex-mediated protein folding cycle using diffracted X-ray tracking[J].Int J Mol Sci,2023,24(19):14850.
[22] JAYASINGHE M,TEWMEY C,STAN G.Versatile substrate protein recognition mechanism of the eukaryotic chaperonin CCT[J].Proteins,2010,78(5):1254-1265.
[23] UCHIKADO Y,INOUE H,HARAGUCHI N,et al.Gene expression profiling of lymph node metastasis by oligomicroarray analysis using laser microdissection in esophageal squamous cell carcinoma[J].Int J Oncol,2006,29(6):1337-1347.
[24] GUAN B, XU M, ZHENG R, et al. Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy[J]. BMC Cancer,2023,23(1):1099.

Memo

Memo:
National Natural Science Foundation of China(No.82173130);国家自然科学基金(编号:82173130);辽宁省沈阳市科学技术计划(编号:22-315-6-16,22-321-33-19);盛京自由研究者计划(编号:201804)
Last Update: 1900-01-01